Methylphenidate Viatris

Methylphenidate Hydrochloride, the active ingredient in Methylphenidate Viatris, is a central nervous system stimulant presented as an oral formulation for oral use. It is used to manage symptoms of attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults.

GNH USA supplies Methylphenidate Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Methylphenidate acts on the central nervous system to improve attention and wakefulness.

- Attention deficit hyperactivity disorder (ADHD): improves focus, reduces hyperactivity and impulsivity. - Narcolepsy: decreases excessive daytime sleepiness and improves alertness.

Methylphenidate may cause a range of adverse reactions. Common side effects are usually mild and transient, while serious or rare events require immediate medical attention.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced food intake leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach pain: abdominal discomfort or nausea.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, tachycardia, or arrhythmias. - Psychotic symptoms: hallucinations or delusional thinking. - Severe allergic reactions: rash, swelling, or anaphylaxis.

Before initiating therapy, clinicians should evaluate several safety considerations.

- Cardiovascular assessment: screen for hypertension, heart disease, or arrhythmias. - Growth monitoring: regularly track height and weight in pediatric patients. - Substance‑use history: assess risk of misuse or dependence. - Psychiatric evaluation: watch for emergence of anxiety, mood changes, or psychosis. - Concomitant MAO inhibitors: avoid use within 14 days of each other. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Methylphenidate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: may increase cardiovascular side effects. - Antihypertensive agents: can reduce blood‑pressure‑lowering effect.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may raise methylphenidate plasma levels. - Antacids: can affect absorption, requiring timing adjustments.